J A Foekens

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.

Urs Eppenberger, Willy Kueng, Jean-Marc Schlaeppi et al. · Journal of Clinical Oncology · 1998 · 220 citations

Medicine, Cancer Biology, Oncology +17

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Monique Schuyer, M.E.L. van der Burg, S.C. Henzen‐Logmans et al. · British Journal of Cancer · 2001 · 96 citations · Full text

Medicine, Cancer Biology, Oncology +17

Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.

S Zeamari, J A Foekens, Martijn F.B.G. Gebbink et al. · PubMed · 1999 · 42 citations

Medicine, Genetics, Oncology +17

The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy.

Y. Zhang, Anieta M. Sieuwerts, Michelle McGreevy et al. · Cancer Research · 2009 · 16 citations

Medicine, Oncology, Breast Oncology +15